III CONGRESO INTERNACIONAL DE COMUNICACIÓN Y SALUD

III CONGRESO INTERNACIONAL DE COMUNICACIÓN Y SALUD

25 y 26 de abril de 2024

Facultad de Ciencias de la Información

Universidad Complutense de Madrid (UCM)

 

https://eventos.ucm.es/110571/section/48293/iii-congreso-internacional-de-comunicacion-y-salud-cicys-2024.html

An Overview of Short- and Long-Term Adverse Outcomes and Complications of Perinatal Depression on Mother and Offspring

An Overview of Short- and Long-Term Adverse Outcomes and Complications of Perinatal Depression on Mother and Offspring

 

Wafaa Mohamed Korany (1), Diaa Marzouk Abd el-Hamid (1,2), Mohamed Farouk Allam (1,2)*

 

1. Department of Family Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

2. Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

 

Universal Journal of Obstetrics and Gynecology 2024;3:870.

 

DOI: 10.31586/ujog.2024.870

 

Abstract 

Antenatal and postpartum major depressive episode (MDE) according to Diagnostic and Statistical Manual of Mental Disorders 5^th Edition (DSM-V) is defined as either daily sustained sad mood or lack of enjoyment or desire for a minimum two weeks plus four associated manifestations (only three if the two major symptoms are present) that start throughout pregnancy or during the first 4 weeks postpartum respectively: 1) Unintentional notable slimming up or down; 2) Sleepiness or sleeplessness; 3) Tiredness sensation; 4) Guilty or futility sensation; 5) Declined concentration capacity; 6) Frequent suicidal thoughts; 7) Psychomotor excitation or delay. Perinatal depression carries vital and adverse consequences on mother’s psychosocial aspects of life, pregnancy and delivery outcomes, her interrelations specifically with the new born with poorer overall health and influences negatively on offspring from the intrauterine life passing by complicated delivery experiencing hard unstable childhood reaching unhealthy adolescence and adulthood. These negative consequences necessitate a great attention for prevention, screening and prompt treatment for antenatal and postnatal depression to prevent such disastrous effects.

 

Keywords: Adverse Outcomes; Complications; Negative Impact; Perinatal Depression; Antepartum Depression; Mother; Foetus; Child.

 

Korany, W. M., Abd el-Hamid, D. M., & Allam, M. F. (2024). An Overview of Short- and Long-Term Adverse Outcomes and Complications of Perinatal Depression on Mother and Offspring. Universal Journal of Obstetrics and Gynecology, 3(1), 1–4.

 

https://www.scipublications.com/journal/index.php/ujog/article/view/870

Fractures Among Egyptian Males With Fragility Hip Fractures in the Emergency Room of Ain Shams University Hospitals

Fractures Among Egyptian Males With Fragility Hip Fractures in the Emergency Room of Ain Shams University Hospitals

Adel A. Abbas (1), Mohamed F. Allam (2), Hala S. Sweed (1), Samia A. Abdul-Rahman (1), Walaa W. Ali (1).

 

1) Geriatrics, Ain Shams University, Cairo, EGY. 2) Preventive Medicine and Public Health, University of Cordoba, Cordoba, ESP. 3) Family Medicine, Ain Shams University, Cairo, EGY.

 

Cureus 15(12): e49960.

 

DOI: 10.7759/cureus.49960

 

Abstract

Background. Fragility fractures are linked to significant costs for society as well as significant pain and suffering, disability, and even death. It is well-recognized that osteoporosis-related fragility fractures raise the risk of subsequent fragility fractures. One of the most frequent osteoporotic fractures brought on by low bone mineral density and other risk factors is vertebral fractures. Considering that most vertebral fractures are asymptomatic and not clinically identified, proactive screening could stop additional impairment.

Objective. The current study aims to determine the prevalence and risk factors of hidden vertebral fractures in Egyptian males who have fragility hip fractures.

Patients and methods. A cross-sectional case-control study examining the correlation of risk factors between cases (fragility hip fracture and vertebral fractures) and a control group (fragility hip fracture without vertebral fracture) was carried out from September 2020 to September 2021 on patients visiting the orthopedic emergency department of a university hospital in Cairo, Egypt. Males who presented to the emergency room (ER) with fragility hip fractures and were 40 years of age or older met our inclusion criteria. For every patient who presented with a fragility hip fracture, standard lateral and anteroposterior radiographs of the dorso-lumbar spine were taken.

Results. A total of 43,935 patients visited the orthopedic emergency room (ER) throughout the study period; 13,034 of those patients were men, accounting for 29.7% of all orthopedic ER visits. Our inclusion criteria for fragility hip fractures were met by 132 male participants. The screening lumbosacral plain X-rays identified 27 (20.5%) of the 132 patients as having concomitant vertebral fractures in addition to the fragility hip fractures. Concomitant hidden vertebral fractures among Egyptian males with other fragility fractures, particularly fragility hip fractures, are predicted by the number of co-morbid diseases, hypertension, and continuous use of steroids and anti-epileptics.

Conclusion. Most fragility fractures are avoidable. Because one fragility fracture increases the likelihood of others, early detection is crucial. To prevent complications and mortality, it is important to identify and manage individuals who have a fragility hip fracture as they frequently have concurrent hidden vertebral fractures. Predictive risk factors for fragility vertebral fractures include hypertension, the number of concomitant illnesses, and chronic drugs (anti-epileptics and steroids).

 

Keywords: Ain Shams University, Egypt, Male, Vertebral Fracture, Hip Fracture, Osteoprosis, Fragility Fracture.

 

Abbas A A, Allam M F, Sweed H S, et al. (December 05, 2023) Proportion of Hidden Vertebral Fractures Among Egyptian Males With Fragility Hip Fractures in the Emergency Room of Ain Shams University Hospitals. Cureus 15(12): e49960. DOI 10.7759/cureus.49960

 

https://www.cureus.com/articles/207101-proportion-of-hidden-vertebral-fractures-among-egyptian-males-with-fragility-hip-fractures-in-the-emergency-room-of-ain-shams-university-hospitals?utm_medium=email&utm_source=transaction#!/

Role of Probiotics and Colchicine in COVID-19 Management?

Role of Probiotics and Colchicine in COVID-19 Management?

Samar Osama Ahmed Hassan (1), Ahmed Nour El-Din Hassan (2), Manal Sabry Mohamed (3), Mina Michael Nesim (3), Mohamed Nabil Badawy Al Ashram (3), Mohamed Farouk Allam (1,4)

 

(1) Department of Family Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt

(2) Department of Clinical Pharmacology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

(3) Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt

(4) Department of Community Medicine, Faculty of Medicine, October 6 University, Cairo, Egypt

 

Universal Journal of Gastroenterology and Hepatology 2023;1(1):14–16.

 

DOI: 10.31586/ujgh.2023.772

 

Abstract

 

Background: Coronavirus disease 2019 (COVID-19) is a newly emerging human disease caused by a novel coronavirus, causing a global pandemic crisis. Probiotics and/or colchicine may be considered as options for treatment since they have anti-viral, anti-inflammatory, and immunomodulatory effects. The aim of the current review was to assess the effectiveness of probiotic supplements and colchicine on symptoms, duration, and progression of mild and moderate cases of COVID-19 infection. Review: A randomized, double-blind, placebo-controlled trial in the United States with 182 participants who were randomly assigned to receive daily oral probiotic (Lactobacillus rhamnosus) LGG or placebo for 28 days. The study indicated that LGG is well-tolerated and is associated with a delay in the onset of COVID-19 infection, a reduction in the incidence of symptoms, and alterations in the structure of the gut microbiome when administered as post-exposure prophylaxis within seven days of exposure. Colchicine may lessen mortality and the need for mechanical ventilation in mild-to-moderate COVID-19 patients, according to a systematic review and meta-analysis. Conclusion: Probiotics and/or colchicine may be viable treatment options for COVID-19 patients. To examine the efficacy of probiotics and colchicine in the treatment of COVID-19, it is necessary to conduct additional clinical trials and provide clinicians with evidence, as there are currently insufficient studies to support this conclusion.

 

Keywords: Probiotics, Colchicine, COVID-19, Management, Clinical trials, Review.

 

Universal Journal of Gastroenterology and Hepatology 2023;1(1):14–16.

 

https://www.scipublications.com/journal/index.php/ujgh/article/view/772

Effectiveness of Probiotics for Treatment of COVID-19: A Systematic Review and Meta-analysis

Effectiveness of Probiotics for Treatment of COVID-19: A Systematic Review and Meta-analysis

Hadeer Abdel-Aleem Hassan Mohamed Tawfik (1), Mohamed Nazmy Farres (2), Rasha Samir (2,3), Mohamed Nabil Badawy Al Ashram (2), Mina Michael Nesim (2), Mohamed Farouk Allam (1*)

 

(1) Department of Family Medicine, Faculty of Medicine, Ain Shams University, Egypt

(2) Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Egypt

(3) Departemnt of Internal Medicine, Armed Forces College of Medicine, Egypt

 

Universal Journal of Gastroenterology and Hepatology 2023;1(1):17–25.

 

DOI: 10.31586/ujgh.2023.735

 

Abstract

 

Background: Recently specific interactions and crosslinks between the gut microbiota and the lungs have been recognized, particularly with regard to respiratory immune and anti-microbial reactions. This is often known as the “gut-lung axis” or “a common mucosal immunological system”. Objective: The aim of the current systematic review was to evaluate evidence, from published clinical trials and cohort studies, if probiotics may have an effect in improving and managing COVID-19 symptoms. Materials and methods: The available studies were searched through a comprehensive search of electronic databases that included PubMed, Science Direct, Scirus, ISI Web of Knowledge, Google Scholar and CENTRAL (Cochrane Central Register of Controlled Trials), using a combination of the following keywords: “COVID-19 OR SARS-CoV-2 AND Microbiota OR Probiotics” OR “Gut Lung Axis”. The literature was reviewed until August 31, 2022. Results: Only 3 studies were included. One of them evaluated the efficacy of probiotics in COVID-19 patients to obtain complete remission of all signs and symptoms. The clinical trial proves that probiotics have a significant effect on complete remission of all signs and symptoms of COVID-19 patients with statistical significant difference. Only one clinical trial out of the 3 included studies had evaluated the need for O2 therapy during the study between the probiotics and control groups, but without statistical significant difference. No statistical significant difference between the probiotics group and placebo group was observed regarding fatal prognosis during the only clinical trial that measured death as an outcome. Conclusion: We couldn’t judge on these results as they are insufficient data for pooling and meta-analysis. However, what we can say is “Most probably Probiotics have no role in treatment of COVID-19 infection”.

 

Keywords: COVID-19, Probiotics, Management, Meta-analysis, Systematic Review.

 

Universal Journal of Gastroenterology and Hepatology 2023;1(1):17–25.

 

https://www.scipublications.com/journal/index.php/UJGH/article/view/735